Immunological markers for predicting the response to immunotherapy in non-small cell lung cancer
Itroduction. Immune checkpoint inhibitors have become the standard of care for patients with advanced non-small cell lung cancer. However, despite the determination of programmed death-ligand 1 expression in clinical practice, which determines the effectiveness of therapy, up to 80 % of patients wit...
| Hoofdauteurs: | , , , , , , , , |
|---|---|
| Formaat: | Artikel |
| Taal: | Russian |
| Gepubliceerd in: |
ABV-press
2022-06-01
|
| Reeks: | Успехи молекулярной онкологии |
| Onderwerpen: | |
| Online toegang: | https://umo.abvpress.ru/jour/article/view/441 |